Walter L Vervenne
Overview
Explore the profile of Walter L Vervenne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoge R, Detert Oude Weme S, Vervenne W, van Berlo-van de Laar I, Van Herpen C, Roorda L, et al.
Ther Drug Monit
. 2022 Aug;
44(6):755-761.
PMID: 36006609
Aim: This study examined whether anthropometric and body composition parameters such as body surface area (BSA), lean body mass (LBM), and total body weight (TBW) are correlated with docetaxel clearance...
2.
Krens S, Lubberman F, van Egmond M, Jansman F, Burger D, Hamberg P, et al.
Int J Cancer
. 2021 Jan;
148(11):2799-2806.
PMID: 33428771
Co-treatment with gastric acid suppressants (GAS) in patients taking anticancer drugs that exhibit pH-dependant absorption may lead to decreased drug exposure and may hamper drug efficacy. In our study, we...
3.
Notohardjo J, Kuppen M, Westgeest H, van Moorselaar R, Mehra N, Coenen J, et al.
Eur Urol Focus
. 2020 May;
7(4):788-796.
PMID: 32362484
Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of...
4.
Lubberman F, Gelderblom H, Hamberg P, Vervenne W, Mulder S, Jansman F, et al.
Clin Pharmacol Ther
. 2019 May;
106(5):1076-1082.
PMID: 31125423
Pazopanib is taken fasted in a fixed oral daily dose of 800 mg. We hypothesized that ingesting pazopanib with food may improve patients' comfort and reduce gastrointestinal (GI) adverse events....
5.
Bouman-Wammes E, van den Berg H, de Munck L, Beeker A, Smorenburg C, Vervenne W, et al.
Eur J Cancer
. 2017 Dec;
90:1-9.
PMID: 29268139
Background: Docetaxel is standard first-line chemotherapy for patients with metastatic castration-resistant prostate carcinoma (mCRPC). Docetaxel re-challenge has never been tested in a prospective randomised controlled study. As some studies support...
6.
Eichelberg C, Vervenne W, De Santis M, Fischer von Weikersthal L, Goebell P, Lerchenmuller C, et al.
Eur Urol
. 2015 May;
68(5):837-47.
PMID: 25952317
Background: Understanding how to sequence targeted therapies for metastatic renal cell carcinoma (mRCC) is important for maximisation of clinical benefit. Objectives: To prospectively evaluate sequential use of the multikinase inhibitors...
7.
Morak M, Richel D, van Eijck C, Nuyttens J, van der Gaast A, Vervenne W, et al.
Radiother Oncol
. 2010 Nov;
98(2):261-4.
PMID: 21075468
Background And Purpose: To investigate the efficacy and toxicity of a short intensive Uracil/Tegafur (UFT) based chemoradiotherapy scheme combined with celecoxib in locally advanced pancreatic cancer. Material And Methods: The...
8.
Van Cutsem E, Vervenne W, Bennouna J, Humblet Y, Gill S, Van Laethem J, et al.
J Clin Oncol
. 2009 Mar;
27(13):2231-7.
PMID: 19307500
Purpose: Treatment with gemcitabine provides modest benefits in patients with metastatic pancreatic cancer. The addition of erlotinib to gemcitabine shows a small but significant improvement in overall survival (OS) versus...
9.
Westerterp M, Boermeester M, Omloo J, Hulshof M, Vervenne W, Lutter R, et al.
Cancer Immunol Immunother
. 2008 Apr;
57(12):1837-47.
PMID: 18398607
Background: To compare immune responses following neoadjuvant chemoradiation therapy in combination with hyperthermia plus surgery to those induced by surgery alone in patients with oesophageal cancer. Methods: Thirty-two patients with...
10.
Siegel-Lakhai W, Beijnen J, Vervenne W, Boot H, Keessen M, Versola M, et al.
Clin Cancer Res
. 2007 Aug;
13(15 Pt 1):4495-502.
PMID: 17671135
Purpose: This phase I study was designed to determine the optimally tolerated regimen (OTR), safety, and clinical activity of lapatinib in combination with FOLFOX4 [oxaliplatin/leucovorin/5-fluorouracil (5-FU)] in patients with solid...